Author:
Wessels Uwe,Zadak Markus,Weidmann Anja Manuela,Stuchly Thomas,Stubenrauch Kay-Gunnar
Abstract
AbstractIntravitreally administered biotherapeutics can elicit local and systemic immune responses with potentially serious clinical consequences. However, little is known about the mechanisms of ocular antidrug immune response, the incidence of ocular antidrug antibodies (ADAs), and the relationship between ocular and systemic ADA levels. Bioanalytical limitations and poor availability of ocular matrices make studies of ocular immunogenicity particularly challenging. We have recently reported a novel bioanalytical ADA assay and shown its applicability for the ADA detection in ocular matrices. In the present study, we used this assay to analyze a large set of preclinical samples from minipig and cynomolgus monkeys treated with different ocular biotherapeutics. We found a significant association between the incidence of ADAs in plasma and ocular fluids after a single intravitreal administration of the drugs. Importantly, none of the animals with ADA-negative results in plasma had detectable ADAs in ocular fluids and systemic ADA response always preceded the appearance of ocular ADAs. Overall, our results suggest the systemic origin of ocular ADAs and support the use of plasma as a surrogate matrix for the detection of ocular ADA response.
Graphical Abstract
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Vandivort TC, Horton DB, Johnson SB. Regulatory and strategic considerations for addressing immunogenicity and related responses in biopharmaceutical development programs. J Clin Transl Sci. 2020;4:547–55.
2. Guideline on Immunogenicity assessment of therapeutic proteins. European Medicines Agency, Committee for Medicinal Products for Human Use; 2017 [Internet]. [cited 2022 Aug 1]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf. Accessed Oct 2022
3. Immunogenicity assessment for therapeutic protein products. Guidance for Industry. U.S. Department of Health and Human Services, Food and Drug Administration; 2014 [Internet]. [cited 2022 Aug 1]. Available from: https://www.fda.gov/media/85017/download. Accessed Oct 2022
4. Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration. Cochrane Db Syst Rev. 2019;2019:CD005139.
5. Kiss S, Dugel PU, Khanani AM, Broder MS, Chang E, Sun GH, et al. Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis. Clin Ophthalmol Auckl N Z. 2018;12:1625–35.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Miniature Swine Use in Toxicology Studies;Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays;2024
2. 2022 White Paper on Recent Issues in Bioanalysis: Enzyme Assay Validation, BAV for Primary End Points, Vaccine Functional Assays, Cytometry in Tissue, LBA in Rare Matrices, Complex NAb Assays, Spectral Cytometry, Endogenous Analytes, Extracellular Vesicles Part 2 – Recommendations on Biomarkers/CDx, Flow Cytometry, Ligand-Binding Assays Development & Validation; Emerging Technologies; Critical Reagents Deep Characterization;Bioanalysis;2023-08